raltitrexed (D 1694)

04/01/2003 - "Raltitrexed has proven efficacy in the treatment of advanced colorectal cancer and has an acceptable toxicity profile. "
01/01/2021 - "This study aimed to assess the safety and efficacy of raltitrexed use in patients with metastatic colorectal cancer who developed significant toxicities after fluoropyrimidine-based treatment. "
03/04/2023 - "Raltitrexed is well known to be effective in the treatment of colorectal cancer in China. "
01/01/2021 - "Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer."
01/01/2019 - "S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial."

10/15/1991 - "ICI D1694 cured the L1210:ICR ascitic tumor in mice at 0.4 mg/kg daily for 5 days (maximum tolerated dose, approximately 50 mg/kg).(ABSTRACT TRUNCATED AT 400 WORDS)"
01/01/1991 - "Current studies with 3H-ICI D1694 are aimed at demonstrating metabolism to polyglutamates in tumor cells. "
01/01/2022 - "Moreover, raltitrexed significantly inhibited tumor cell colony formation, arrested the cell cycle, decreased the mitochondrial membrane potential, and induced apoptosis. "
01/01/2019 - "GI cancer patients who developed CV toxicity as a result of FPs and those with significant CV risk factors receiving raltitrexed were included in this analysis. "
01/01/2019 - "Patient, tumor, and treatment characteristics, as well as clinical outcomes of all consecutively treated patients with raltitrexed at the Royal Marsden Hospital between October 1998 and July 2011 were examined. "

04/01/2002 - "This review outlines the appropriate management of patients treated with raltitrexed, whether as monotherapy or in combination, and discusses the preliminary results of combination studies with raltitrexed in a range of tumour types including advanced CRC, malignant mesothelioma, gastric, pancreatic, head and neck, and non-small-cell lung cancers. "
12/20/2007 - "A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma."
01/15/2003 - "Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study."
02/01/2002 - "In a phase II trial of raltitrexed/oxaliplatin, 14 objective responses were confirmed in 72 patients (25%) with malignant pleural mesothelioma. "
11/01/2001 - "In a phase I study, the combination of oxaliplatin and raltitrexed was shown to be active against malignant pleural mesothelioma. "

11/01/2021 - "This study aimed to evaluate efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC) using real-world evidence. "
11/01/2021 - "Efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real-world study."
02/22/2023 - "However, reports of the clinical outcomes of raltitrexed-based transarterial chemoembolization (TACE) or drug-eluting beads TACE (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC) are rare. "
02/22/2023 - "Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma."
01/01/2022 - "Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma."

05/01/2006 - "Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II study."
11/01/2005 - "The aim of this prospective multicenter phase II study was to evaluate the feasibility, gastrointestinal and hematological acute toxicity of raltitrexed in combination with radiotherapy in rectal cancer patients. "
04/01/2003 - "The aim of this phase I study was to determine the recommended dose of raltitrexed in combination with radiotherapy in patients with unresectable/recurrent rectal cancer. "
04/01/2003 - "Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study."
08/01/2000 - "This study demonstrates that raltitrexed can be combined with postoperative radiotherapy for treatment of patients with Dukes' stage B or C rectal cancer. "